Washington DC (PRWEB) February 28, 2013
The birth control resource center at DrugRisks.com is alerting women who have taken the oral contraceptives Yaz or Yasmin of new information showing French health officials have asked regulators with the European Union to limit prescriptions of these drugs due to concerns over blood clot risks.
“The resource center’s goal is to improve consumer safety through education. By providing the latest drug alerts, studies, recalls and legal news, patients can discuss options with their doctor and decide if they need legal advice. This applies to reports from Europe as well,” explains DrugRisks representative Ryan Mayer.
DrugRisks contains studies from the British Medical Journal and FDA which warned birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.*
Now, the resource center has added information showing France will request that European Union regulators modify prescription guidelines for third and fourth-generation birth control drugs like Yaz and Yasmin in order to limit use.** The move comes after a recent announcement that France will no longer reimburse patients for drugs like Yaz over blood clot concerns.**
In the United States, Bayer has admitted they face as many as 12,000 Yaz lawsuits from women who took the drugs over claims of blood clot injuries like DVT and pulmonary embolism.***
Due to the number of patients filing a claim, they were consolidated to a special federal Multi-District Litigation court in Illinois. The case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).
DrugRisks has also reported that Bayer began settling Yaz lawsuits last spring, and has so far spent as much as $750 million to settle around 3,500 cases.***
Anyone who suffered a Yaz blood clot, DVT, stroke or Pulmonary Embolism after taking the drug is urged to contact the Drug Risks Resource Center or speak with a lawyer for more information.
DrugRisks cautions that patients should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisks.com.
*British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints"
***Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012